• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4657933)   Today's Articles (129)   Subscriber (51256)
For: Shao YHJ, Hong JH, Chen CK, Huang CY. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. Prostate Cancer Prostatic Dis 2023;26:722-729. [PMID: 35662291 PMCID: PMC10638084 DOI: 10.1038/s41391-022-00555-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 05/16/2022] [Accepted: 05/25/2022] [Indexed: 11/09/2022]
Number Cited by Other Article(s)
1
Reiss AB, Vasalani S, Albert J, Drewes W, Li K, Srivastava A, De Leon J, Katz AE. The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer. MEDICINA (KAUNAS, LITHUANIA) 2024;60:1727. [PMID: 39596912 PMCID: PMC11596556 DOI: 10.3390/medicina60111727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 10/09/2024] [Accepted: 10/17/2024] [Indexed: 11/29/2024]
2
Patel S, Zhu K, Dave CV, Ghajar M, Zhang Y, Saraiya B, Bandera EV, Khosrow-Khavar F. Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies. Eur Urol Oncol 2024:S2588-9311(24)00213-X. [PMID: 39343637 DOI: 10.1016/j.euo.2024.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2024] [Revised: 08/11/2024] [Accepted: 09/10/2024] [Indexed: 10/01/2024]
3
Yaxley JW, Fitzgerald B. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis "PCAN-23-0763R". Prostate Cancer Prostatic Dis 2024:10.1038/s41391-024-00873-5. [PMID: 39075162 DOI: 10.1038/s41391-024-00873-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2024] [Revised: 07/04/2024] [Accepted: 07/10/2024] [Indexed: 07/31/2024]
4
DE Nunzio C, Nacchia A, Grimaldi MC, Turchi B, Rovesti L, Franco A, Guarnotta G, Voglino O, Mancini E, Baldassarri V, Lombardo R, Cicione A, Tubaro A. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database. Minerva Urol Nephrol 2024;76:203-209. [PMID: 38498298 DOI: 10.23736/s2724-6051.23.05611-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/20/2024]
5
Merseburger AS, Bakshi G, Chen DY, Chiong E, Jabbour M, Joung JY, Lai AYH, Lawrentschuk N, Le TA, Ng CF, Ng CT, Ong TA, Pang JST, Rabah DM, Ragavan N, Sase K, Suzuki H, Teo MMH, Uemura H, Woo HH. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network. World J Urol 2024;42:156. [PMID: 38483562 PMCID: PMC10940372 DOI: 10.1007/s00345-024-04852-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 02/05/2024] [Indexed: 03/17/2024]  Open
6
Poon DMC, Tan GM, Chan K, Chan MTY, Chan TW, Kan RWM, Lam MHC, Leung CLH, Wong KCW, Kam KKH, Ng CF, Chiu PKF. Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Front Oncol 2024;14:1345322. [PMID: 38357197 PMCID: PMC10864500 DOI: 10.3389/fonc.2024.1345322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 01/15/2024] [Indexed: 02/16/2024]  Open
7
Cicione A, Nacchia A, Guercio A, Gravina C, Franco A, Grimaldi MC, Tema G, Lombardo R, Tubaro A, De Nunzio C. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate Cancer Prostatic Dis 2023;26:765-771. [PMID: 36641533 DOI: 10.1038/s41391-022-00640-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 12/27/2022] [Accepted: 12/30/2022] [Indexed: 01/15/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA